




Receipt
erw

PATENT
ATTORNEY DOCKET NO. 50304/064001

Certificate of Mailing: Date of Deposit: March 29, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Heidi Wright
Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	DECKMYN et al.	Art Unit:	1644
Serial No.:	10/049,868	Examiner:	Maher M. Haddad
Filed:	June 4, 2002	Customer No.:	21559
Title:	CELL LINES, LIGANDS AND ANTIBODY FRAGMENTS FOR USE IN PHARMACEUTICAL COMPOSITIONS FOR PREVENTING AND TREATING HAEMOSTASIS DISORDERS		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION TO CORRECT FILING RECEIPT

Applicants request that the enclosed filing receipt be corrected as follows.

Under Foreign Applications please replace "02/02/2002" with --02/02/2000--.


A copy of the incorrect filing receipt showing the above-noted amendment is attached. In addition, Applicants include a copy of the "Claim for Priority" document as filed May 29, 2002, which indicates that EP 00102032.0 was filed February 2, 2000.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.


Respectfully submitted,

Date: 29 March 2005



James D. DeCamp, Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



UNITED STATES PATENT AND TRADEMARK OFFICE

50304-064001

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/049,868	06/04/2002	1644	813	522-1778	11	21	10

21559
CLARK & ELBING LLP
101 FEDERAL STREET
BOSTON, MA 02110

RECEIVED

MAR 28 2005

CLARK & ELBING LLP

CONFIRMATION NO. 2345
CORRECTED FILING RECEIPT
OC000000015535705
OC000000015535705

Date Mailed: 03/22/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Hans Deckmyn, Linden, BELGIUM;
Nancy Cauwenberghs, Londerzeel, BELGIUM;

COPY

Power of Attorney: The patent practitioners associated with Customer Number 21559.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP00/07874 08/08/2000

Foreign Applications

UNITED KINGDOM 9918788.2 08/10/1999
EUROPEAN PATENT OFFICE (EPO) 00102032.0 ~~02/02/2000~~ 02/02/2000

If Required, Foreign Filing License Granted: 03/22/2005

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/049,868**

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ******Title**

Cell lines, ligands and antibody fragments for use in pharmaceutical compositions for preventing and treating haemostasis disorders

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED


The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



522-1778

101 Rec'd PCT/PTO 04 JUN 2002

10/049868

#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF)

Hans Deckmyn and Nancy Cauwenberghs)

SERIAL NO: 10/049,868)

FILED: February 11, 2002)

FOR: Cell Lines, Ligands and Antibody Fragments)
For Use In Pharmaceutical Compositions for)
Preventing and Treating Haemostasis)
Disorders)

COPY

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to "Commissioner of Patents, Washington, D.C. 20231", on May 29, 2002

Name of person signing Linda Mueller

Signature

CLAIM FOR PRIORITY

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231


Dear Sir:

Under the International Convention, for the purposes of priority, applicant claims the benefit of European Application No. 00102032.0 filed February 2, 2000.

A certified copy of said application is appended hereto.

DATE: May 29, 2002

Respectfully submitted,


William M. Lee, Jr.
Registration No. 26,935

LEE, MANN, SMITH, MCWILLIAMS
SWEENEY & OHLSON
P.O. Box 2786
Chicago, Illinois 60690-2786
(312) 368-1300
Fax (312) 368-0034